Cefpodoxime pulsatile - MiddleBrook
Alternative Names: Cefpodoxime PULSYS™ - MiddleBrook; Pulsatile cefpodoxime - MiddleBrookLatest Information Update: 02 Oct 2021
At a glance
- Originator Advancis Pharmaceutical
- Developer MiddleBrook Pharmaceuticals
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 26 Aug 2009 No development reported - Preclinical for Bacterial infections in USA (PO)
- 28 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals
- 31 Dec 2003 Preclinical trials in Bacterial infections in USA (PO)